Colonoscopy; Surveillance Indications

Slides:



Advertisements
Similar presentations
Colorectal Cancer Awareness in TN: Risk Factors, Screening, Outreach Keith D. Gray, M.D. Assistant Professor of Surgery Division of Surgical Oncology The.
Advertisements

Implementing NICE guidance
Surveillance/ Screening Colonoscopy for Colorectal Cancer
CT COLONOGRAPHY. CRC TRENDS  Incidence decreased by 7%  Mortality decreased by 20%  Five year survival rates increased by 12%
Colorectal Cancer Screening and Surveillance FDA Advisory Committee March, 2002 David Lieberman MD Chief, Division of Gastroenterology Oregon Health Sciences.
Spotlight on Colorectal Cancer Screening 1 1. Home Screening for Colon Cancer
The Adenoma/Carcinoma Sequence in the Colon
Surveillance colonoscopy after polypectomy – how frequent? Dr Chu Ming Leong Tuen Mun Hospital 1.
Update on Screening of Gastrointestinal Diseases Niraj Jani, M.D. Greater Baltimore Medical Center 1/30/15.
Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007.
Familial Colorectal Cancers Francis M. Giardiello, M.D. The Johns Hopkins University.
Laparoscopic Colon Surgery
DR Jameel Tariq Miro.  Lifetime incidence 5%  90% of cases occur after age 50  One-third of patients with colorectal cancer die from the disease 
Cancer Genetics for Primary Care Sara Levene Registered Genetic Counsellor.
Screening and Early Diagnosis of Colorectal Cancer
Colorectal Cancer Screening John Pelzel MD Sleepy Eye Medical Center.
Joint Hospital Surgical Grand Round 19 June 2004.
Clinical Practice Screening for Colorectal Cancer David A. Lieberman, M.D. N Engl J Med Volume 361(12): September 17, 2009.
Asymptomatic UC patients on an immunomodulator with persistent moderate mucosal inflammation should either add a biologic or switch to a biologic William.
Colorectal cancer Khayal AlKhayal MD,FRCSC
Bowel Screening in Scotland – Current Challenges and Possible Solutions Prof. Bob Steele Ninewells Hospital, University of Dundee.
Colon Cancer Screening
Genetics & Colorectal Cancer
A Colonscope is used to remove or biopsy polyps  Night Prep.
D. M. Kruss MD Kill the Cancer Do Screening now! Daniel M. Kruss, M.D. Kill the Cancer Do Screening now! Daniel M. Kruss, M.D.
Di fronte alla displasia intestinale Colon e Retto G C Sturniolo Università degli Studi di Padova Dipartimento di Scienze Chirurgiche e Gastroenterologiche.
Colonoscopic surveillance for prevention of colorectal cancer in people with ulcerative colitis, Crohn’s disease or adenomas NICE CG March 2011.
Controversies Regarding Cancer Surveillance in IBD Stephen B. Hanauer, MD Professor of Medicine & Clinical Pharmacology Chief, Section of Gastroenterology.
High risk population in GI field how we can find them? Ahmad Shavakhi MD Associate professor of gastroenterology.
ANDREW LATCHFORD BSc, MBBS, MD, FRCP CONSULTANT GASTROENTEROLOGIST
Colorectal carcinoma Dr.Mohammadzadeh.
Should colonoscopy be performed one year out from colorectal cancer resection? Alexandra Kent, Philip Thompson, Prof Alan Horgan, Mr Paul Hainsworth Newcastle.
Slides last updated: June 2015 CRC: CLINICAL FEATURES.
An Evidence Based Approach to Colorectal Cancer Screening J. C. Ryan, M.D. Associate Professor of Medicine UCSF and SF VAMC 9/22/2014.
1 Colorectal Cancer # 2 Cancer Killer # 2 Cancer Killer SCREENING SAVES LIVES.
Change in bowel habits … 60 year old male Complains of progressive constipation for the past 6 months.
IBD Patient Update Case Vignettes 12 November 2011.
Familial Risk and Surveillance of Colon and Rectum Malcolm Dunlop Academic Coloproctology & Colon Cancer Genetics Group University of Edinburgh & Western.
סרטן מעי גס אבחון מוקדם מניעה טיפול מונע ד"ר הוברט אילה מנהלת המרכז לגידולים במערכת העיכול מכון שרת הדסה עין כרם.
Colon polyps Peter Stanich, MD
Cancer Prevention Eyad Alsaeed, MD,FRCPC Consultant Radiation Oncology PSHOC KFMC.
Which of the following is/are true regarding Ulcerative Colitis (UC)? A. Females are affected more then males. B. Surgery is curative. C. The most consistent.
The effects of inadequate preparation quality for colonoscopy Eric Sherer and Michael Catlin August 20 th, 2010 HSR&D Work-in-Progress 1.
Screening for Colorectal Cancer (CRC) Nov, 2007 A Aljebreen, FRCPC Division of Gastroenterology KKUH, Riyadh.
 Detection of metachronous tumors  Recognition of local recurrence Follow-up Flexible endocsopy.
Colorectal Cancer Screening Colorectal Cancer Screening VT SGNA Conference VT SGNA Conference October 24, 2015 October 24, 2015 Lynn Butterly, MD Lynn.
Colonic cancer screening in high risk groups
Crohn’s Colitis SR Brown Colorectal Surgeon Sheffield Teaching Hospitals.
Yield of colonoscopy for advanced neoplasia in a population-based setting Bernard DENIS, Jacques PICOT, Jean François VIES, Marjorie MUSSO, Paul François.
CT Colonography vs Colonoscopy for the Detection of Advanced Neoplasia David H. Kim, M.D., Perry J. Pickhardt, M.D., Andrew J. Taylor, M.D., Winifred K.
Do you have 3 or more affected relatives? (2 or less)
Towards Global Eminence K Y U N G H E E U N I V E R S I T Y Colonoscopy Surveillance After Colorectal Cancer Resection: Recommendations of the US Multi-Society.
(A) Surveillance colonoscopies for detecting dysplasia and preventing colorectal carcinoma. (B) Management of visible lesions at endoscopy. A visible lesion.
1 Yize R. Wang, MD, PhD, John R. Cangemi, MD, Edward V. Loftus Jr, MD and Michael F. Picco, MD, PhD Am J Gastroenterol 2013;108:444–449 F1 김혁 / Prof. 김효종.
GASTROINTESTINAL ENDOSCOPY Volume 78, No. 3 : 2013 F1 김태영
High frequency of early colorectal cancer in inflammatory bowel disease M W M D Lutgens, F P Vleggaar, M E I Schipper, P C F Stokkers, C J van der Woude,
GI Path Exam 2. Most common neoplastic polyp? Most common location and size of colonic hyperplastic polyps?
D. M. Kruss MD Colon Cancer How to nip it in the bud! Daniel M. Kruss, M.D. Colon Cancer How to nip it in the bud! Daniel M. Kruss, M.D.
Colorectal Cancer: Risk Prevention and Diagnosis
27th Annual Winter CME Conference
Bowel cancer screening update GP education event 28 Nov 2017
Colorectal Cancer Screening and Postoperative Follow-Up
Repeat Colonoscopy Recommendations
Module 4: Colorectal Cancer
Colitis associated cancer: risk and surveillance
Colorectal Cancer Mr Eoghan Condon, MD,FRCSI.
Improving Quality Measures for Colonoscopy and CRC Prevention
Steven H Itzkowitz, Noam Harpaz  Gastroenterology 
Polyps of the Colon and Rectum
Risks of interval colorectal cancer in a FIT-based screening program
Presentation transcript:

Colonoscopy; Surveillance Indications SR Brown Colorectal Surgeon Sheffield Teaching Hospitals

Colorectal cancer screening in high risk groups Gut 2002;51(Suppl V)

Screening vs Surveillance Asymptomatic population Surveillance Previous symptoms/high risk

High risk groups Previous colorectal cancer Acromegaly Ureterosigmoidostomy Hereditary and Familial bowel cancer IBD Previous polyps

Aims To discuss salient aspects of guidelines To highlight recent developments in colonoscopic surveillance

Colorectal cancer surveillance

Colorectal cancer surveillance; aims Detect recurrence Diagnose and treat metachronous neoplasia Evaluate anastomosis

Colorectal cancer surveillance ‘Incidence metachronous tumours 5-10%’ Metachronous cancers approx. 2% Cochrane review 1.3% (18/1342) Metachronous adenomas 22% (425/1923)

Colorectal cancer surveillance Synchronous/‘early’ metachronous cancers 4% 0.6% ‘missed’ due to incomplete colon exam

Familial cancer surveillance

Familial Cancer Summary Family group Screening procedure Age at initial screen Screening procedure and interval 2 FDR with CRC Colonoscopy At 1st consult or age 35-40 years (whichever later) If initial clear repeat at age 55 1 FDR<45 yr with CRC

Lifetime risk of colorectal cancer Risk Group Risk (of dying) General population 1:50 Any family history 1:17 One affected relative <45 years 1:10 Two affected relatives 1:6 Houlston et al. 1970

Familial Cancer Summary Family group Screening procedure Age at initial screen Screening procedure and interval 2 FDR with CRC Colonoscopy At 1st consult or age 35-40 years (whichever later) If initial clear repeat at age 55 1 FDR<45 yr with CRC

Chances of preventing death with screening colonoscopy 35 year old with FDR<45 years 1 in 25,000 people aged 30-39 develop colorectal cancer per year Relative risk = 5 Risk of cancer = 1 in 5000 in per year Assume asymptomatic cancer dwell time of 3 years Chance of detecting cancer 1 in 1660

Familial Cancer Summary Family group Screening procedure Age at initial screen Screening procedure and interval 2 FDR with CRC Colonoscopy At 1st consult or age 35-40 years (whichever later) If initial clear repeat at age 55 1 FDR<45 yr with CRC

Chances of preventing death with screening colonoscopy 55 year old with FDR<45 years 1 in 1,630 people aged 50-59 develop colorectal cancer per year Relative risk = 3 Risk of cancer = 1 in 543 per year Assume asymptomatic cancer dwell time of 3 years Chance of detecting cancer 1 in 181

Hereditary cancer surveillance

Hereditary Cancer Summary Family group Screening procedure Age at initial screen Screening procedure and interval FAP Genetic testing Flexi sig+OGD Puberty Flexi sig yearly Colectomy if +ve HNPCC Colonoscopy +/- OGD 25 yrs or 5 yrs before earliest CRC in family 2 yearly colonoscopy and OGD Juvenile polyposis Peutz-Jegher Genetic testing Colonoscopy + OGD

IBD surveillance

IBD Summary Disease group Screening procedure Age at initial screen Screening procedure and interval UC or Crohn’s coloitis Colonoscopy+ biopsies every 10cm After 8 years for pan colitis, 15 years for left sided colitis 3 yrly 2nd decade, 2yrly 3rd decade, yrly thereafter UC + PSC Colonoscopy At diagnosis PSC Annually

Controversies ? Survival advantage (Cochrane review 2004) No clear evidence May allow earlier detection of cancer ?lead-time bias

Controversies Ongoing inflammation increases risk Dysplasia as a marker for cancer Reliability Detection Histological interpretation

Controversies;detection Pan-chromoscopy and targeted biopsy (Rutter 2004) Back-to-back colonoscopy Conventional then dye-spray Conventional no dysplasia in 2904 random biopsies Targeted 157 biopsies 7 patients with dysplasia

Ileo-anal pouch surveillance

Pouch cancer 15 case reports 10 residual rectal mucosa 5 ??pouch mucosa All pre-existing dysplasia 8 had cancer in original resection 9 had mucosectomy

Surveillance recommendations Pouchoscopy 1st year then 2-3 yearly Increased surveillance (yearly) if Pre-existing dysplasia/cancer PSC Mucosectomy if high risk

Polyp surveillance

Summary Read guidelines!!